Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Apremilast has been prescribed to more than 250,000 patients with plaque psoriasis or psoriatic arthritis since it was approved in 2014.
The US Food and Drug Administration (FDA) has approved apremilast (Otezla), commonly used to treat diseases such as psoriatic arthritis (PsA), Behcet’s Syndrome, and plaque psoriasis, as a generic drug in 10, 20, and 30 mg tablets.
The approval for the oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP) was awarded to Unichem Laboratories.
The therapy is currently approved in the US for the treatment of active PsA, moderate to severe plaque psoriasis in patients eligible for phototherapy or systemic therapy, and oral ulcers associated with Behcet’s Disease in adults.
Since it was initially approved in 2014, the treatment has been prescribed to more than 250,000 patients with moderate-to-severe plaque psoriasis or active psoriatic arthritis in the US.
Recently, during the American College of Rheumatology (ACR) Convergence 2020, investigators found the selective PDE4 inhibitor is associated with early and sustained benefit in patients regardless of their biologic treatment.
Investigators concluded apremilast was associated with slightly greater achievements in initiated and sustained clinical improvement among patients with psoriatic arthritis who have not taken prior biologics.
No Benefit for Ankylosing Spondylitis
However, the approval comes just days after new data showed apremilast did not yield patients with active ankylosing spondylitis (AS). In the phase 3, multicenter, double-blind, placebo-controlled study, the researchers randomized 490 patients with active AS to receive either apremilast 20 mg twice daily, apremilast 30 mg twice daily, or a placebo.
At Week 104, the mean changes from baseline in the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) were 0.83 (3.6), 0.98 (2.2), and 0.57 (1.9) in patients initially randomized to placebo, apremilast 20 mg, and apremilast 30 mg, respectively.